{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:22:15Z","timestamp":1795022535161,"version":"4.10.1"},"reference-count":64,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"43","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10,24]]},"abstract":"<jats:p>\n                    This study aimed to investigate the correlations between short- and long-term efficacy of immune checkpoint inhibitors (ICIs) and pretreatment laboratory\/imaging parameters in advanced non-small cell lung cancer (NSCLC), and to construct risk prediction models. We enrolled 137 NSCLC patients with stage IIIB-IV disease who completed 4 cycles of PD-1\/PD-L1 inhibitor monotherapy or combination therapy. All participants underwent pretreatment laboratory assessments encompassing inflammatory markers, lymphocyte subsets, tumor biomarkers, coagulation profiles, and contrast-enhanced computed tomography (CE-CT) scans. The primary endpoints were objective response rate (ORR) and overall survival (OS), with progression-free survival (PFS) as the secondary endpoint. Univariate and multivariate logistic regression analyses were performed to identify significant predictors of short-term treatment response and develop an efficacy prediction model. For long-term outcomes, univariate and multivariate Cox proportional hazards regression analyses were conducted to establish a prognostic risk model. The final models were presented as nomograms and validated through receiver operating characteristic (ROC) curve analysis, calibration curves, and decision curve analysis (DCA). CD4\n                    <jats:sup>+<\/jats:sup>\n                    T-cell count (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.007), fibrinogen (FIB,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.047), and mediastinal lymph node enlargement (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.028) emerged as independent predictors of ORR. The prediction model demonstrated an area under the ROC curve (AUC) of 0.838, with bootstrap validation (1000 resamples) yielding a mean AUC of 0.867. Calibration analysis, DCA, and clinical impact curve (CIC) collectively confirmed the model\u2019s robust predictive performance. For OS, metastatic site (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.007), neutrophil-to-lymphocyte ratio (NLR,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.025), carbohydrate antigen 125 (CA125,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.020), cytokeratin 19 fragment (CYFRA 21-1,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.004), FIB (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001), and pleural effusion (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;\u2005.001) were identified as significant prognostic determinants. The model achieved AUC values of 0.858 and 0.860 for 1- and 2-year survival prediction, respectively. Calibration plots revealed excellent concordance between predicted and observed survival probabilities at both timepoints. Furthermore, DCA indicated superior net clinical benefit of the prognostic model compared to random chance models across threshold probability ranges. Comprehensive prediction models integrating clinical characteristics, laboratory biomarkers, and imaging parameters were developed for both short- and long-term efficacy evaluation of immunotherapy, offering clinically actionable guidance for personalizing treatment strategies in advanced NSCLC.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000045224","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T19:01:22Z","timestamp":1761332482000},"page":"e45224","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Combined laboratory and imaging indicators to construct risk models for predicting immunotherapy efficacy and prognosis in non-small cell lung cancer: An observational study (STROBE compliant)"],"prefix":"10.1097","volume":"104","author":[{"given":"Xinyu","family":"Bai","sequence":"first","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailan","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiying","family":"Bai","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhui","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng","family":"Bi","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senyang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Chengde Medical University, Chengde, Hebei, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Immunology, Chengde Medical University, Chengde, Hebei, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Immunology, Chengde Medical University, Chengde, Hebei, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Immunology, Chengde Medical University, Chengde, Hebei, P.R. China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8547-1326","authenticated-orcid":false,"given":"Li","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Chengde Medical University, Chengde, Hebei, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261118","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants.","volume":"135","author":"Xia","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"R2-20261118","doi-asserted-by":"crossref","first-page":"a037895","DOI":"10.1101\/cshperspect.a037895","article-title":"Tumor immunology and immunotherapy of non-small-cell lung cancer.","volume":"12","author":"Cascone","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R3-20261118","doi-asserted-by":"crossref","first-page":"799455","DOI":"10.3389\/fimmu.2021.799455","article-title":"Therapeutic implications of tumor microenvironment in lung cancer: focus on immune checkpoint blockade.","volume":"12","author":"Genova","year":"2022","journal-title":"Front Immunol"},{"key":"R4-20261118","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1186\/s12885-021-08662-2","article-title":"The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Cancer"},{"key":"R5-20261118","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-line immunotherapy for non-small-cell lung cancer.","volume":"40","author":"Reck","year":"2022","journal-title":"J Clin Oncol"},{"key":"R6-20261118","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1016\/j.apsb.2021.01.003","article-title":"Alterations of DNA damage response pathway: biomarker and therapeutic strategy for cancer immunotherapy.","volume":"11","author":"Jiang","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"R7-20261118","doi-asserted-by":"crossref","first-page":"6536","DOI":"10.3390\/ijms22126536","article-title":"TMB in NSCLC: a broken dream?","volume":"22","author":"Bravaccini","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R8-20261118","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1158\/1078-0432.CCR-15-1678","article-title":"Microsatellite instability as a biomarker for PD-1 blockade.","volume":"22","author":"Dudley","year":"2016","journal-title":"Clin Cancer Res"},{"key":"R9-20261118","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1158\/1078-0432.CCR-21-1935","article-title":"Immunotherapy of MSI cancer: facts and hopes.","volume":"30","author":"Wilbur","year":"2024","journal-title":"Clin Cancer Res"},{"key":"R10-20261118","doi-asserted-by":"crossref","first-page":"107255","DOI":"10.1016\/j.lungcan.2023.107255","article-title":"Genomic characteristics and prognosis of lung cancer patients with MSI-H: a cohort study.","volume":"181","author":"Tian","year":"2023","journal-title":"Lung Cancer"},{"key":"R11-20261118","doi-asserted-by":"crossref","first-page":"1265202","DOI":"10.3389\/fimmu.2023.1265202","article-title":"Comparison of different predictive biomarker testing assays for PD-1\/PD-L1 checkpoint inhibitors response: a systematic review and network meta-analysis.","volume":"14","author":"Shi","year":"2023","journal-title":"Front Immunol"},{"key":"R12-20261118","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1200\/JCO.22.01990","article-title":"Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study.","volume":"41","author":"Novello","year":"2023","journal-title":"J Clin Oncol"},{"key":"R13-20261118","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12943-023-01714-0","article-title":"Regulatory cells and the effect of cancer immunotherapy.","volume":"22","author":"Iglesias-Escudero","year":"2023","journal-title":"Mol Cancer"},{"key":"R14-20261118","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation.","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"R15-20261118","doi-asserted-by":"crossref","first-page":"e28617","DOI":"10.1097\/MD.0000000000028617","article-title":"The relationship between NLR\/PLR\/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.","volume":"101","author":"Liu","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"R16-20261118","doi-asserted-by":"crossref","first-page":"11206","DOI":"10.1038\/s41598-024-84469-y","article-title":"Peripheral inflammatory factors as prognostic predictors for first-line PD-1\/PD-L1 inhibitors in advanced non-small cell lung cancer.","volume":"15","author":"Jin","year":"2025","journal-title":"Sci Rep"},{"key":"R17-20261118","doi-asserted-by":"crossref","first-page":"1016085","DOI":"10.3389\/fgene.2022.1016085","article-title":"Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: a multicenter study.","volume":"13","author":"Liu","year":"2022","journal-title":"Front Genet"},{"key":"R18-20261118","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.3389\/fimmu.2018.01613","article-title":"Circulating T cell subpopulations correlate with immune responses at the tumor site and clinical response to PD1 inhibition in non-small cell lung cancer.","volume":"9","author":"Manjarrez-Ordu\u00f1o","year":"2018","journal-title":"Front Immunol"},{"key":"R19-20261118","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/CBM-2009-0124","article-title":"Biological markers in lung cancer: a clinician\u2019s perspective.","volume":"6","author":"Tufman","year":"2010","journal-title":"Cancer Biomark"},{"key":"R20-20261118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2020.07.028","article-title":"Soluble PD-L1 and circulating CD8+PD-1+ and NK cells enclose a prognostic and predictive immune effector score in immunotherapy treated NSCLC patients.","volume":"148","author":"Mazzaschi","year":"2020","journal-title":"Lung Cancer"},{"key":"R21-20261118","doi-asserted-by":"crossref","first-page":"e24550","DOI":"10.1002\/jcla.24550","article-title":"Coagulation parameters in lung cancer patients: a systematic review and meta-analysis.","volume":"36","author":"Bayleyegn","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"R22-20261118","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/cancers12010067","article-title":"Is there an interplay between immune checkpoint inhibitors, thromboprophylactic treatments and thromboembolic events? Mechanisms and impact in non-small cell lung cancer patients.","volume":"12","author":"Nichetti","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R23-20261118","doi-asserted-by":"crossref","first-page":"e7742","DOI":"10.1097\/MD.0000000000007742","article-title":"Diagnostic value of contrast-enhanced CT scans in identifying lung adenocarcinomas manifesting as GGNs (ground glass nodules).","volume":"96","author":"Gao","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R24-20261118","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.athoracsur.2018.08.015","article-title":"Comparing two imaging methods for follow-up of lung cancer treatment: a randomized pilot study.","volume":"107","author":"Gambazzi","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"R25-20261118","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1002\/jcsm.13568","article-title":"Body composition derangements in lung cancer patients treated with first-line pembrolizumab: a multicentre observational study.","volume":"15","author":"Trestini","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R26-20261118","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1186\/s12885-023-11512-y","article-title":"Impact of BMI on the survival outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis.","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"R27-20261118","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1208\/s12248-020-00525-1","article-title":"Keytruda and PD-L1: a real-world example of co-development of a drug with a predictive biomarker.","volume":"23","author":"Emancipator","year":"2020","journal-title":"AAPS J"},{"key":"R28-20261118","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/COC.0000000000000828","article-title":"Prognostic factors of second-line immune checkpoint inhibitors in patients with advanced-stage non-small cell lung cancer: a multicenter, retrospective study.","volume":"44","author":"Roh","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"R29-20261118","doi-asserted-by":"crossref","first-page":"135","DOI":"10.21037\/tlcr-21-815","article-title":"Association between the baseline tumor size and outcomes of patients with non-small cell lung cancer treated with first-line immune checkpoint inhibitor monotherapy or in combination with chemotherapy.","volume":"11","author":"Uehara","year":"2022","journal-title":"Transl Lung Cancer Res"},{"key":"R30-20261118","doi-asserted-by":"crossref","first-page":"10807","DOI":"10.1038\/s41598-023-37736-3","article-title":"Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer.","volume":"13","author":"Inomata","year":"2023","journal-title":"Sci Rep"},{"key":"R31-20261118","doi-asserted-by":"crossref","first-page":"654","DOI":"10.3389\/fonc.2020.00654","article-title":"Pretreatment neutrophil-to-lymphocyte ratio (NLR) may predict the outcomes of advanced non-small-cell lung cancer (NSCLC) patients treated with immune checkpoint inhibitors (ICIs).","volume":"10","author":"Li","year":"2020","journal-title":"Front Oncol"},{"key":"R32-20261118","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/j.acra.2023.10.039","article-title":"Development and validation of a machine learning-based model using CT radiomics for predicting immune checkpoint inhibitor-related pneumonitis in patients with NSCLC receiving anti-PD1 immunotherapy: a multicenter retrospective casecontrol study.","volume":"31","author":"Zhang","year":"2024","journal-title":"Acad Radiol"},{"key":"R33-20261118","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.3390\/cancers15153829","article-title":"A radiomics-clinical model predicts overall survival of non-small cell lung cancer patients treated with immunotherapy: a multicenter study.","volume":"15","author":"Yolchuyeva","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R34-20261118","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences.","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"R35-20261118","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/imr.12444","article-title":"Neutrophils in cancer.","volume":"273","author":"Treffers","year":"2016","journal-title":"Immunol Rev"},{"key":"R36-20261118","doi-asserted-by":"crossref","first-page":"103806","DOI":"10.1016\/j.critrevonc.2022.103806","article-title":"Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors.","volume":"179","author":"Rebuzzi","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"key":"R37-20261118","doi-asserted-by":"crossref","first-page":"107970","DOI":"10.1016\/j.isci.2023.107970","article-title":"Using peripheral immune-inflammatory blood markers in tumors treated with immune checkpoint inhibitors: an INVIDIa-2 study sub-analysis.","volume":"26","author":"Anpalakhan","year":"2023","journal-title":"iScience"},{"key":"R38-20261118","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1007\/s00262-022-03262-w","article-title":"The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"R39-20261118","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00262-017-2092-x","article-title":"Post-treatment neutrophil-to-lymphocyte ratio at week 6 is prognostic in patients with advanced non-small cell lung cancers treated with anti-PD-1 antibody.","volume":"67","author":"Suh","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"R40-20261118","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2017.07.024","article-title":"Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.","volume":"111","author":"Diem","year":"2017","journal-title":"Lung Cancer"},{"key":"R41-20261118","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jgo.2018.08.004","article-title":"Inflammatory markers and overall survival in older adults with cancer.","volume":"10","author":"Nishijima","year":"2019","journal-title":"J Geriatr Oncol"},{"key":"R42-20261118","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1007\/s12325-020-01229-w","article-title":"Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and outcomes with nivolumab in pretreated Non-Small Cell Lung Cancer (NSCLC): a large retrospective multicenter study.","volume":"37","author":"Russo","year":"2020","journal-title":"Adv Ther"},{"key":"R43-20261118","doi-asserted-by":"crossref","first-page":"3610038","DOI":"10.1155\/2022\/3610038","article-title":"Prognostic value of Lymphocyte-to-Monocyte Ratio (LMR) in cancer patients undergoing immune checkpoint inhibitors.","volume":"2022","author":"Wan","year":"2022","journal-title":"Dis Markers"},{"key":"R44-20261118","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.01.013","article-title":"Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.","volume":"106","author":"Bagley","year":"2017","journal-title":"Lung Cancer"},{"key":"R45-20261118","doi-asserted-by":"crossref","first-page":"433","DOI":"10.21037\/atm.2019.08.116","article-title":"Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis.","volume":"7","author":"Wang","year":"2019","journal-title":"Ann Transl Med"},{"key":"R46-20261118","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1634\/theoncologist.2018-0563","article-title":"Peripheral blood markers identify risk of immune-related toxicity in advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.","volume":"24","author":"Pavan","year":"2019","journal-title":"Oncologist"},{"key":"R47-20261118","doi-asserted-by":"crossref","first-page":"e22964","DOI":"10.1002\/jcla.22964","article-title":"Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.","volume":"33","author":"Liu","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"R48-20261118","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/s41586-019-1914-8","article-title":"Tertiary lymphoid structures improve immunotherapy and survival in melanoma.","volume":"577","author":"Cabrita","year":"2020","journal-title":"Nature"},{"key":"R49-20261118","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/s41586-023-06199-x","article-title":"CD4+ T cell-induced inflammatory cell death controls immune-evasive tumours.","volume":"618","author":"Kruse","year":"2023","journal-title":"Nature"},{"key":"R50-20261118","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s12890-022-01951-x","article-title":"Association of lymphocyte subsets with efficacy and prognosis of immune checkpoint inhibitor therapy in advanced non-small cell lung carcinoma: a retrospective study.","volume":"22","author":"Yan","year":"2022","journal-title":"BMC Pulm Med"},{"key":"R51-20261118","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/s00262-024-03738-x","volume":"73","author":"Liu","year":"2024","journal-title":"Cancer Immunol Immunother"},{"key":"R52-20261118","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1 CD8+ T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients.","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R53-20261118","doi-asserted-by":"crossref","first-page":"e004440","DOI":"10.1136\/jitc-2021-004440","article-title":"Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer.","volume":"10","author":"Lopez de Rodas","year":"2022","journal-title":"J ImmunoTher Cancer"},{"key":"R54-20261118","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/j.1600-0897.2007.00513.x","article-title":"Natural killer (NK) cells from killers to regulators: distinct features between peripheral blood and decidual NK cells.","volume":"58","author":"Santoni","year":"2007","journal-title":"Am J Reprod Immunol"},{"key":"R55-20261118","doi-asserted-by":"crossref","first-page":"1758835920952994","DOI":"10.1177\/1758835920952994","article-title":"CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors.","volume":"12","author":"Dall\u2019Olio","year":"2020","journal-title":"Ther Adv Med Oncol"},{"key":"R56-20261118","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1186\/s12885-023-11312-4","article-title":"Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study.","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"key":"R57-20261118","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.rmed.2012.11.007","article-title":"Clinical and prognostic significance of coagulation assays in lung cancer.","volume":"107","author":"Tas","year":"2013","journal-title":"Respir Med"},{"key":"R58-20261118","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/crj.12144","article-title":"The prognostic value of D-dimer in lung cancer.","volume":"9","author":"\u0130nal","year":"2015","journal-title":"Clin Respir J"},{"key":"R59-20261118","doi-asserted-by":"crossref","first-page":"15831","DOI":"10.1002\/cam4.6222","article-title":"Plasma D-dimer and interleukin-6 are associated with treatment response and progression-free survival in advanced NSCLC patients on anti-PD-1 therapy.","volume":"12","author":"Chen","year":"2023","journal-title":"Cancer Med"},{"key":"R60-20261118","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/cam4.1428","article-title":"Albumin-to-fibrinogen ratio as a promising biomarker to predict clinical outcome of non-small cell lung cancer individuals.","volume":"7","author":"Li","year":"2018","journal-title":"Cancer Med"},{"key":"R61-20261118","doi-asserted-by":"crossref","first-page":"115731","DOI":"10.1016\/j.bcp.2023.115731","article-title":"Lymph node metastasis and tumor-educated immune tolerance: Potential therapeutic targets against distant metastasis.","volume":"215","author":"Peng","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"R62-20261118","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.lungcan.2022.08.002","article-title":"Pathological complete response to neoadjuvant chemoimmunotherapy correlates with peripheral blood immune cell subsets and metastatic status of mediastinal lymph nodes (N2 lymph nodes) in non-small cell lung cancer.","volume":"172","author":"Ma","year":"2022","journal-title":"Lung Cancer"},{"key":"R63-20261118","doi-asserted-by":"crossref","first-page":"1800349","DOI":"10.1183\/13993003.00349-2018","article-title":"ERS\/EACTS statement on the management of malignant pleural effusions.","volume":"52","author":"Bibby","year":"2018","journal-title":"Eur Respir J"},{"key":"R64-20261118","doi-asserted-by":"crossref","first-page":"6184","DOI":"10.3390\/cancers14246184","article-title":"The effect of pleural effusion on prognosis in patients with non-small cell lung cancer undergoing immunochemotherapy: a retrospective observational study.","volume":"14","author":"Nishimura","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045224","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T17:01:13Z","timestamp":1795021273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000045224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":64,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000045224","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"2024-01-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-08","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}